Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Lawrence Otto Klein net worth and biography

Lawrence Klein Biography and Net Worth

COO of CRISPR Therapeutics

Dr. Klein has served as our Chief Operating Officer since January 2020 and remains responsible for business development activities; before that, Dr. Klein served as our Chief Business Officer from January 2019 to January 2020, our Senior Vice President, Business Development and Strategy from November 2017 through December 2018 and as our Vice President, Strategy from February 2016 to November 2017. Before joining our company, from October 2014 to February 2016, Dr. Klein was an Associate Partner at McKinsey & Company, where he was a leader in the biotech practice and served a number of biotechnology companies on a wide range of topics from strategy to operations. Dr. Klein received a Ph.D. from Stanford University, where he conducted research in the field of T cell immunology, and he holds a B.S. from the University of Wisconsin at Madison. Dr. Klein also has served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN), a biotechnology company, since September 2019 and Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company, since September 2021.

What is Lawrence Otto Klein's net worth?: The estimated net worth of Lawrence Otto Klein is at least $1.54 million as of January 15th, 2021. Dr. Klein owns 28,666 shares of CRISPR Therapeutics stock worth more than $1,540,224 as of April 26th. This net worth estimate does not reflect any other investments that Dr. Klein may own. Additionally, Dr. Klein receives a salary of $675,000.00 as COO at CRISPR Therapeutics. Learn More about Lawrence Otto Klein's net worth.
How old is Lawrence Otto Klein?: Dr. Klein is currently 40 years old. There are 4 older executives and no younger executives at CRISPR Therapeutics. The oldest executive at CRISPR Therapeutics is Dr. Matthew Porteus M.D., Ph.D., Scientific Founder & Advisory Board Member, who is 56 years old. Learn More on Lawrence Otto Klein's age.
What is Lawrence Otto Klein's salary?: As the COO of CRISPR Therapeutics AG, Dr. Klein earns $675,000.00 per year. The highest earning executive at CRISPR Therapeutics is Dr. Samarth Kulkarni, CEO & Director, who commands a salary of $1,180,000.00 per year. Learn More on Lawrence Otto Klein's salary.
How do I contact Lawrence Otto Klein?: The corporate mailing address for Dr. Klein and other CRISPR Therapeutics executives is BAARERSTRASSE 14, ZUG V8, CH-6300. CRISPR Therapeutics can also be reached via phone at (141) 561-3277 and via email at [email protected]. Learn More on Lawrence Otto Klein's contact information.
Has Lawrence Otto Klein been buying or selling shares of CRISPR Therapeutics?: Lawrence Otto Klein has not been actively trading shares of CRISPR Therapeutics over the course of the past ninety days. Most recently, Lawrence Otto Klein sold 25,000 shares of the business's stock in a transaction on Friday, January 15th. The shares were sold at an average price of $215.20, for a transaction totalling $5,380,000.00. Following the completion of the sale, the chief operating officer now directly owns 28,666 shares of the company's stock, valued at $6,168,923.20. Learn More on Lawrence Otto Klein's trading history.
Who are CRISPR Therapeutics' active insiders?: CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Kurt Emster (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.
Are insiders buying or selling shares of CRISPR Therapeutics?: In the last year, insiders at the sold shares 11 times. They sold a total of 178,992 shares worth more than $12,029,834.57. The most recent insider tranaction occured on April, 15th when CEO Samarth Kulkarni sold 19,582 shares worth more than $1,173,157.62. Insiders at CRISPR Therapeutics own 4.1% of the company. Learn More about insider trades at CRISPR Therapeutics.
Information on this page was last updated on 4/15/2024.

Lawrence Otto Klein Insider Trading History at CRISPR Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/15/2021	Sell	25,000	$215.20	$5,380,000.00	28,666
6/24/2020	Sell	65,088	$75.93	$4,942,131.84	58,666
5/11/2020	Sell	25,000	$60.40	$1,510,000.00	45,000
7/11/2019	Sell	20,000	$50.02	$1,000,400.00	31,579

Lawrence Otto Klein Buying and Selling Activity at CRISPR Therapeutics

CRISPR Therapeutics Company Overview

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Today's Range

Now: $53.73

$52.75

$54.15

50 Day Range

MA: $71.13

$53.73

$89.12

2 Week Range

Now: $53.73

$37.55

$91.10

Volume

1,238,443 shs

Average Volume

1,807,807 shs

Market Capitalization

$4.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

From Paradigm Press | Ad

Click here to find out that this 8,788% cryptocurrency is.

Lawrence Klein Biography and Net Worth

What is Lawrence Otto Klein's net worth?

How old is Lawrence Otto Klein?

What is Lawrence Otto Klein's salary?

How do I contact Lawrence Otto Klein?

Has Lawrence Otto Klein been buying or selling shares of CRISPR Therapeutics?

Who are CRISPR Therapeutics' active insiders?

Are insiders buying or selling shares of CRISPR Therapeutics?